Brendan Manning, Ph.D. is a Professor in the Department of Molecular Metabolism and Director of the PhD Program in Biological Sciences in Public Health at the Harvard T.H. Chan School of Public Health. He received his PhD from Yale University in 2000 and was a postdoctoral fellow at Harvard Medical School. In 2004, Dr. Manning became the first faculty member hired in the then newly established Department of Genetics and Complex Diseases (later changed to Molecular Metabolism) at Harvard-Chan. Dr. Manning was an inaugural recipient of the National Cancer Institute’s Outstanding Investigator Award.
Research in the Manning lab is defining the molecular interface between cellular signaling networks and metabolic networks, as it relates to both normal physiology and diseases with metabolic dysregulation as a key feature, including cancer, diabetes, and aging-related diseases. Research efforts are focused in part on defining the regulatory mechanisms and functions of a signaling network converging on the tuberous sclerosis complex (TSC) protein complex and the mammalian target of rapamycin (mTOR), which relay an array of extracellular and intracellular growth signals to control the balance between anabolic and catabolic metabolism in cells, tissues, and tumors.